{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T19:24:10Z","timestamp":1766690650926},"reference-count":15,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T00:00:00Z","timestamp":1370304000000},"content-version":"vor","delay-in-days":6760,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[1994,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Fluticasone Propionate Aqueous Nasal Spray (FPANS) contains a topically active glucocorticoid fluticasone propionate which has been used successfully for the treatment of seasonal allergic rhinitis. This multicentre, randomized, double\u2010blind, double\u2010dummy, placebo\u2010controlled, parallel group study was designed to compare the efficacy and tolerability of FPANS with terfenadine tablets or placebo in controlling the symptoms of allergic rhinitis to grass pollen. Two hundred and fourteen patients were treated for 6 weeks during the grass pollen season with either FPANS 200 \u03bcg once daily, terfenadine tablets (60 mg) twice daily or placebo. Efficacy was evaluated by the analysis of symptom\u2010free days and median symptom scores. Patients receiving FPANS had significantly more days free of nasal blockage on waking (<jats:italic>P =<\/jats:italic> 0\u00b7012) and during the day (<jats:italic>P<\/jats:italic> = 0\u00b701) and of rhinorrhoea (<jats:italic>P<\/jats:italic> = 0\u00b7027) than those receiving terfenadine. Additionally, in terms of absolute efficacy, patients receiving FPANS demonstrated significantly more days free of the above symptoms (<jats:italic>P<\/jats:italic> = 0\u00b7017, <jats:italic>P<\/jats:italic> = 0\u00b7028, <jats:italic>P =<\/jats:italic> 0\u00b7004, respectively) and of sneezing (<jats:italic>P<\/jats:italic> &lt; 0\u00b7001) than those receiving placebo. There were no significant differences in symptoms of nasal itching, eye symptoms, of symptoms of drowsiness between the three treatment groups. Patients in the FPANS group had significantly lower median symptom scores for nasal blockage on waking (<jats:italic>P<\/jats:italic> &lt; 0\u00b7001) and during the day (<jats:italic>P<\/jats:italic> &lt; 0\u00b7018) than those in the terfenadine group and significantly lower scores for nasal blockage on waking (<jats:italic>P<\/jats:italic> &lt; 0\u00b7001), sneezing (<jats:italic>P &lt;<\/jats:italic> 0\u00b7013<jats:italic>)<\/jats:italic> and rhinorrhoea (<jats:italic>P =<\/jats:italic> 0\u00b7005) than those in the placebo group. The use of rescue medication was similar in all three treatment groups. Adverse events were similar in nature and frequency in all three treatment groups, most were mild and considered by the investigator at each centre unlikely to be related or unrelated to the study treatment. There were very few clinically significant laboratory abnormalities observed in any group. It is concluded that FPANS (200 \u03bcg once daily) is an effective and well\u2010tolerated treatment for seasonal allergic rhinitis and is significantly more effective than terfenadine (60 mg twice daily) in controlling nasal blockage at all times of the day and rhinorrhoea.<\/jats:p>","DOI":"10.1111\/j.1365-2222.1994.tb03320.x","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T14:23:23Z","timestamp":1370355803000},"page":"1144-1150","source":"Crossref","is-referenced-by-count":22,"title":["A double\u2010blind comparison of fluticasone propionate aqueous nasal spray, terfenadine tablets and placebo in the treatment of patients with seasonal allergic rhinitis to grass pollen"],"prefix":"10.1111","volume":"24","author":[{"given":"R.","family":"DARNELL","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"PECOUD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. H.","family":"RICHARDS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,6,4]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"KappJF.Use of topical corticosteroids in the management of rhinitis. In:SeltipaneGA ed.Rhinitis. Providence: New England and Regional Allergy Proceedings1984;108\u201315."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(88)90166-2"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80069-7"},{"key":"e_1_2_1_5_2","first-page":"156","article-title":"Dose tolerance study of FPANS in patients with seasonal allergic rhinitis","volume":"67","author":"As A","year":"1991","journal-title":"Ann Allergy"},{"issue":"2","key":"e_1_2_1_6_2","first-page":"196s","article-title":"A comparison of the tolerance and systemic effects of FPANS (FP) and beclomethasone dipropionate (BDP) in the healthy volunteers","volume":"1","author":"Harding SM","year":"1988","journal-title":"Eur Respir J"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(08)80004-2"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243050-00009"},{"key":"e_1_2_1_9_2","first-page":"630","article-title":"Intranasal FPANS once daily is more effective than terfenadine twice daily in relieving symptoms of seasonal allergic rhinitis","volume":"89","author":"Bavel J","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_1_10_2","first-page":"332","article-title":"Once daily Fluticasone Propionate Aqueous Nasal Spray is an effective treatment for seasonal allergic rhinitis","volume":"67","author":"Nathan RA","year":"1991","journal-title":"Ann Allergy"},{"key":"e_1_2_1_11_2","first-page":"77","article-title":"Fluticasone Propionate Aqueous Nasal Spray given once a day safely controls the symptoms of seasonal allergic rhinitis","volume":"64","author":"Dockhorn R","year":"1990","journal-title":"Ann Allergy"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(08)80005-4"},{"key":"e_1_2_1_13_2","first-page":"123","article-title":"Terfenadine treatment of fall hay fever","volume":"60","author":"Buckley CE","year":"1988","journal-title":"Ann Allergy"},{"key":"e_1_2_1_14_2","first-page":"132","article-title":"In: Non\u2010parametrics: Statistical methods based on ranks","volume":"81","author":"Lehmann El","year":"1975","journal-title":"San Francisco: Holden-Day Inc."},{"key":"e_1_2_1_15_2","first-page":"403","volume-title":"Biopharmaceutical statistics for drug development","author":"Kock GG","year":"1988"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(88)90220-5"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2222.1994.tb03320.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2222.1994.tb03320.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T23:35:52Z","timestamp":1698104152000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2222.1994.tb03320.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1994,12]]}},"alternative-id":["10.1111\/j.1365-2222.1994.tb03320.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2222.1994.tb03320.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,12]]}}}